Allogene Therapeutics Inc (ALLO) financials
Allogene Therapeutics revenue and earnings by year
Allogene Therapeutics's revenue was $22,000 in the fiscal year to December 31, 2024, down 76.8% from the year before. Net income was -$258 million, -1170863.6% of revenue. Since the fiscal year to December 31, 2021, revenue has shrunk 94.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114 |
| Revenue growth | -76.8% | -39.1% | -99.9% | — |
| Operating income | -273 | -328 | -336 | -180 |
| Operating margin | -1241813.6% | -344986.3% | -215087.2% | -157.9% |
| Net income | -258 | -327 | -340 | -182 |
| Net margin | -1170863.6% | -344489.5% | -218214.1% | -159.6% |
| Diluted EPS | -$1.32 | -$2.09 | -$2.38 | -$1.34 |
| Free cash flow | -201 | -239 | -226 | -206 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ALLO in Markets.
See also: ALLO returns
No forecast, no recommendation. This page describes Allogene Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.